A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 1 study, condition: Diabetes Mellitus, Type 2. The main purpose of this study is to learn about the side effects of LY3437943 when given to participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943, dulaglutide, or placebo given just under the skin. For each participant, the study will last up to about 5 months and will include 16 visits to the study center. Enrolment: 72 participants. Status: completed. No topline or peer-reviewed results are verified for publication on this Record for this study — registry facts only.